Deepanshi Rana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deepanshi Rana has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
1 shared publication - Saumya Das
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, KnowledgePark- II, Greater Noida, 201306 Uttar Pradesh, India
1 shared publication
Latest Publications
- 3 November 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 27
Rapid-Acting Antidepressants: Targeting Neuroplasticity Beyond Monoamines
Depression remains a leading cause of morbidity worldwide, with conventional monoaminergic antidepressants such as SSRIs and SNRIs limited by delayed onset and high rates of treatment resistance. Novel approaches that modulate neuroplasticity, particularly NMDA receptor antagonists like ketamine, have demonstrated rapid efficacy in treatment-resistant depression. Ketamine relieves symptoms within hours by promoting glutamate release, AMPA receptor activation, BDNF–TrkB signaling, and mTOR pathway engagement, leading to synaptic remodeling. This review focuses on ketamine as an adjunct or alternative to monoaminergic therapies, highlighting mechanistic pathways of synaptic scaling and dendritic spine formation. Comparative insights into psychedelics, neurosteroids, and investigational NMDA modulators are also discussed, with emphasis on translational limitations, biomarker feasibility, and ethical challenges in digital therapeutics.
- 3 November 2026
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 27
Rapid-Acting Antidepressants: Targeting Neuroplasticity Beyond Monoamines
Depression remains a leading cause of morbidity worldwide, with conventional monoaminergic antidepressants such as SSRIs and SNRIs limited by delayed onset and high rates of treatment resistance. Novel approaches that modulate neuroplasticity, particularly NMDA receptor antagonists like ketamine, have demonstrated rapid efficacy in treatment-resistant depression. Ketamine relieves symptoms within hours by promoting glutamate release, AMPA receptor activation, BDNF–TrkB signaling, and mTOR pathway engagement, leading to synaptic remodeling. This review focuses on ketamine as an adjunct or alternative to monoaminergic therapies, highlighting mechanistic pathways of synaptic scaling and dendritic spine formation. Comparative insights into psychedelics, neurosteroids, and investigational NMDA modulators are also discussed, with emphasis on translational limitations, biomarker feasibility, and ethical challenges in digital therapeutics.